The Quiet Consolidation Taking Over Neurology
Private equity has spent the last decade working through hospital-adjacent specialties – orthopedics, dermatology, gastroenterology – buying up independent practices and folding them into centrally managed platforms. Neurology held out longer than most. The specialty is complex, referral-heavy, and built on long-term patient relationships that don’t transfer easily to a transactional ownership model. But the holdout is ending. Regional neurology groups across the country are now actively fielding acquisition offers, and a growing number are signing.
The deals are rarely announced with press releases. No ribbon-cutting, no formal statement from the acquiring fund. A practice that has operated under the same name for 20 years quietly rebrands, or doesn’t rebrand at all, while backend billing, staffing, and scheduling shift under new management. Patients often don’t know. Referring physicians sometimes don’t either. That opacity is part of the design.
Why Neurology, Why Now
Neurology generates revenue in ways that suit private equity’s math. Neurologists perform high-value diagnostic procedures – EMG studies, EEGs, sleep studies, ambulatory monitoring – that carry strong reimbursement rates and can be scaled across a platform with shared equipment and centralized reading. A solo neurologist running one EMG lab is leaving margin on the table. A PE-backed platform running ten of them, with standardized protocols and a contracted reading team, captures that margin at scale.
Demand is also structurally favorable. An aging population means more patients presenting with Parkinson’s disease, dementia, epilepsy, peripheral neuropathy, and stroke-related complications. These aren’t elective concerns that patients defer during tight economic periods. Neurology volume is sticky, and the referral pipelines from primary care and hospital systems are well established. For a buyer modeling five-year cash flows, those are attractive inputs.
There is also a supply-side pressure driving physician willingness to sell. Running an independent neurology practice has become genuinely difficult. Prior authorization burdens for neurological medications and procedures have grown substantially. Staffing costs, particularly for experienced neurological nurses and technologists, have risen. Electronic health record compliance and payer contracting complexity require administrative infrastructure that small practices can’t afford efficiently. Selling to a well-capitalized platform removes those headaches, and the upfront check is considerable. For a neurologist in their 50s who doesn’t want to spend another decade managing a business, the calculus is straightforward.
How the Rollup Structure Works
PE-backed neurology rollups typically follow a platform-and-bolt-on model. A fund acquires one established regional group as the anchor – the platform practice – then uses it as the operational base for acquiring smaller groups nearby. The smaller acquisitions are “bolt-ons” that get absorbed into the platform’s infrastructure: same billing system, same payer contracts, same HR and compliance functions. The acquired physicians usually stay on as employees under multi-year contract terms that include compensation guarantees and, in some cases, equity participation in the platform itself.
This model is running in parallel across other specialties. Regional ophthalmology practices have followed a nearly identical acquisition pattern, with PE platforms using the same anchor-and-bolt-on logic to consolidate eye care across geographic markets. The mechanics transfer cleanly to neurology because both specialties share the same fundamental appeal: procedural revenue streams, chronic patient populations, and a fragmented independent practice landscape that is ripe for aggregation.
What Changes After the Sale
The first thing that changes is scheduling. PE-owned practices typically push for higher patient throughput – more visits per neurologist per day, shorter appointment slots, faster follow-up cycles. The logic is operational efficiency, and in theory it increases access. In practice, neurologists who built careers on extended consultations and careful diagnostic workups often find the new pace difficult to sustain without compromising the quality of care they’re used to delivering.
Ancillary services get expanded quickly. If a practice wasn’t running its own EMG lab or offering in-house sleep study referrals, the new ownership will almost certainly build or acquire those capabilities. This isn’t inherently bad for patients – having those services available within the same practice can be convenient. But the financial incentive to order ancillary studies at owned facilities creates a subtle pressure that didn’t exist when the neurologist had no stake in where the test was performed. Regulatory frameworks around physician self-referral offer some guardrails, but they don’t eliminate the dynamic.
Physician autonomy narrows in ways that aren’t always obvious at signing. Drug formularies may shift toward medications preferred by the platform’s contracted pharmacy benefit arrangements. Referral patterns, particularly for imaging and hospital admissions, get shaped by the platform’s network relationships. A neurologist who previously sent complex cases to whichever academic center had the best outcomes for a given condition may find that the new employment agreement includes preferred network provisions that constrain those decisions.
Compensation, at least initially, tends to hold or improve. PE buyers need physicians to stay through the holding period, typically five to seven years, and aggressive post-acquisition pay cuts would accelerate departures and destroy the value they just paid for. The pressure on compensation usually comes later – when the platform is refinanced, when EBITDA targets get revised upward, or when the fund moves toward a secondary sale and the incoming buyer applies fresh pressure to margins. The neurologists who signed on in year one often find that the terms in year four look meaningfully different from what they expected.
Regulatory attention to PE-backed physician practices has grown, with several state attorneys general examining whether consolidation in specific specialties is affecting patient access and pricing. Neurology hasn’t drawn the same scrutiny as anesthesiology or emergency medicine yet, largely because the rollups are still in earlier stages and haven’t generated the kind of billing disputes or coverage crises that trigger public attention. That window may be closing. As neurology platforms grow large enough to dominate referral patterns in mid-sized metro markets, the question of whether consolidation is serving patients or extracting from them will become harder to avoid.
